NeoStem Data From Phase 2 PreSERVE AMI Clinical Trial To Be Presented At American Heart Association Scientific Sessions On 11/17

NeoStem, Inc. NBS, a biopharmaceutical company developing novel cell based therapeutics, announced today scheduling details regarding upcoming presentations at the American Heart Association Scientific Sessions of data from its Phase 2 PreSERVE AMI clinical trial evaluating NBS10 in the treatment of damaged heart muscle following a heart attack. NeoStem also plans to issue a press release following the first presentation and conduct an investor conference call and webcast relating to the data on Tuesday, November 18th, at 8:00 AM EST. American Heart Association Scientific Sessions 2014 Exhibition Booth: 743 Website: http://www.scientificsessions.org Presentation 1 Date and Time: Monday, November 17, 2014, 4:07 PM CST Venue: Room S100ab, McCormick Place, Chicago, Illinois Session: CS.02 – Off the Beaten Pathologies Topic: PreSERVE AMI: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Intracoronary Infusion of Autologous CD34+ Cells in Patients With Left Ventricular Dysfunction Post STEMI Speaker: Dr. Arshed A. Quyyumi, Professor of Medicine at Emory University, Lead Principal Investigator of PreSERVE AMI study Presentation 2 Date and Time: Tuesday, November 18, 2014, 8:00 AM CST Venue: Room S405, McCormick Place, Chicago, Illinois Session: CVS.517 – Use of Progenitor Cells to Improve Cardiac Remodeling Topic: Bone Marrow Cells and Patient Care Speaker: Dr. Douglas Losordo, Chief Medical Officer, NeoStem Investor Conference Call Details Date and Time: Tuesday, November 18, 2014, 8:00 AM EST To access the webcast, visit the Investor Relations section of the Company's website at www.neostem.com/investors/investor-events or call 1-855-235-8282 and provide Conference ID 32811273. An archive of the call will be available approximately two hours after its completion. To access the archived recording, visit the Investor Relations section of the Company's website at www.neostem.com/investors/investor-events. The archive of the call will be available for 90 days following the call. About NBS10 NBS10, also known as AMR-001, the Company's lead candidate in its ischemic repair program, is being developed to treat damaged heart muscle following an acute myocardial infarction (heart attack or AMI). The PreSERVE AMI Phase 2 trial is a 160 patient randomized, double-blind, placebo-controlled clinical trial evaluating NBS10 in patients with post ST segment elevation myocardial infarction (STEMI). Ischemia occurs when the supply of oxygenated blood in the body is restricted. NeoStem seeks to improve oxygen delivery to tissues through the development and formation of new blood vessels. NBS10 is designed to address a significant medical need for which there is currently no effective treatment, potentially improving longevity and quality of life for those suffering a STEMI, and positioning NeoStem to capture a meaningful share of this worldwide market.